Invesaro

Stocks Comparison

CONMED vs LivaNova: revenue, profit, margins and growth compared

CONMED brought in $1.4B of revenue in fiscal 2025, LivaNova $1.4B in fiscal 2025. Revenue changed by +5.2% at CONMED and +10.7% at LivaNova on the year before, so LivaNova grew faster. CONMED kept 3.4% of its revenue as net profit, LivaNova -17.5%. Free cash flow was $150.9M at CONMED and $173.3M at LivaNova.

Side by side, latest fiscal year

CNMDLIVN
Fiscal year endedFY2025 (December 31, 2025)FY2025 (December 31, 2025)
Revenue$1.4B$1.4B
Revenue growth+5.2%+10.7%
Net income$47.1M-$242.5M
Net margin3.4%-17.5%
Free cash flow$150.9M$173.3M
Free cash flow margin11.0%12.5%
Earnings per share (diluted)$1.51-$4.45
Cash$40.8M$635.6M
Debt$834.9M$376.1M
Price to earnings30.1n/a
Market value$1.4B$4.2B
Dividend yield1.32%n/a
Rank by revenue in sector#131 of 523 · Health care#130 of 523 · Health care

Over the years

Revenue
CNMD FY2018: $859.6MCNMD FY2019: $955.1MCNMD FY2020: $862.5MCNMD FY2021: $1BCNMD FY2022: $1BCNMD FY2023: $1.2BCNMD FY2024: $1.3BCNMD FY2025: $1.4BLIVN FY2018: $1.1BLIVN FY2019: $1.1BLIVN FY2020: $934.2MLIVN FY2021: $1BLIVN FY2022: $1BLIVN FY2023: $1.2BLIVN FY2024: $1.3BLIVN FY2025: $1.4BFY18FY19FY20FY21FY22FY23FY24FY25
CNMD $1.4BLIVN $1.4B
Net income
CNMD FY2018: $40.9MCNMD FY2019: $28.6MCNMD FY2020: $9.5MCNMD FY2021: $62.5MCNMD FY2022: -$80.6MCNMD FY2023: $64.5MCNMD FY2024: $132.4MCNMD FY2025: $47.1MLIVN FY2018: -$189.4MLIVN FY2019: -$157.6MLIVN FY2020: -$348.8MLIVN FY2021: -$135.8MLIVN FY2022: -$86.2MLIVN FY2023: $17.5MLIVN FY2024: $63.2MLIVN FY2025: -$242.5MFY18FY19FY20FY21FY22FY23FY24FY25
CNMD $47.1MLIVN -$242.5M
Net margin
CNMD FY2018: 4.8%CNMD FY2019: 3.0%CNMD FY2020: 1.1%CNMD FY2021: 6.2%CNMD FY2022: -7.7%CNMD FY2023: 5.2%CNMD FY2024: 10.1%CNMD FY2025: 3.4%LIVN FY2018: -17.1%LIVN FY2019: -14.5%LIVN FY2020: -37.3%LIVN FY2021: -13.1%LIVN FY2022: -8.4%LIVN FY2023: 1.5%LIVN FY2024: 5.0%LIVN FY2025: -17.5%FY18FY19FY20FY21FY22FY23FY24FY25
CNMD 3.4%LIVN -17.5%
Revenue growth
CNMD FY2019: +11.1%CNMD FY2020: -9.7%CNMD FY2021: +17.2%CNMD FY2022: +3.4%CNMD FY2023: +19.1%CNMD FY2024: +5.0%CNMD FY2025: +5.2%LIVN FY2019: -2.1%LIVN FY2020: -13.8%LIVN FY2021: +10.8%LIVN FY2022: -1.3%LIVN FY2023: +12.9%LIVN FY2024: +8.7%LIVN FY2025: +10.7%FY19FY20FY21FY22FY23FY24FY25
CNMD +5.2%LIVN +10.7%
Free cash flow
CNMD FY2018: $58.2MCNMD FY2019: $75.1MCNMD FY2020: $51.5MCNMD FY2021: $96.9MCNMD FY2022: $11.6MCNMD FY2023: $106.3MCNMD FY2024: $153.9MCNMD FY2025: $150.9MLIVN FY2018: $83.3MLIVN FY2019: -$115.8MLIVN FY2020: -$114.4MLIVN FY2021: $77.1MLIVN FY2022: $43.4MLIVN FY2023: $39.9MLIVN FY2024: $135.9MLIVN FY2025: $173.3MFY18FY19FY20FY21FY22FY23FY24FY25
CNMD $150.9MLIVN $173.3M

Fiscal years as each company reports them; the two may end in different months.

Questions about CONMED and LivaNova

Which is bigger by revenue, CONMED or LivaNova?

LivaNova is bigger by revenue: $1.4B in fiscal 2025, against $1.4B for CONMED in fiscal 2025.

Which keeps more of its revenue as profit, CONMED or LivaNova?

CONMED had a net margin of 3.4% in fiscal 2025; LivaNova had -17.5% in fiscal 2025.

Which grew revenue faster, CONMED or LivaNova?

In their latest fiscal years revenue changed by +5.2% at CONMED and +10.7% at LivaNova.

Where do these numbers come from?

From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.

More comparisons

Compare more companies